TELOTRISTAT is an adjunct to somatostatin analogue therapy for the long-term treatment of carcinoid syndrome to improve symptom control in adult patients with metastatic neuroendocrine tumours.
The company who makes telotristat has applied to Health Canada for approval with an expected Notice of Compliance in late September 2018. Once approved, it will go through the Common Drug Review (CDR) process for funding considerations.
CNETS Canada is registered as a patient advocacy organization with CADTH to provide patient advocacy group input into the CDR process
es. It is incredibly important that we do whatever we can to ensure that all NET patients have access to the best treatment options and participating in this process is one of the critical ways in which we do this.
CNETS Canada is conducting a survey to get input from NET patients who have experience with telotristat, in order to develop our patient group submission report to the Common Drug Review (CDR).
Input from patients is vital to the CDR process as it ensures that patient and caregiver values are considered appropriately during a drug review.
Please consider providing us with important feedback by completing an anonymous survey by September 29th, 2018.